Every Form 4 that Vir Biotechnology, Inc. (VIR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VIR filings page.
Vir Biotechnology, Inc. director Robert J. More reported entity-level share transfers involving 16,000 shares of common stock. On 2026-08-11, 8,000 shares held directly for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred for no consideration, and 8,000 shares were correspondingly recorded as held indirectly by APNG 1 in connection with the vesting of restricted stock unit awards. Following these transactions, More reports 40,656 shares held directly and 517,917 shares held indirectly through APNG 1, with beneficial ownership of the indirect holdings disclaimed except for his pecuniary interest.
Vir Biotechnology, Inc. director Timothy Coughlin reported compensation-related equity grants. He acquired two awards of 8,000 shares of common stock each at no cost, in the form of restricted stock units under the company’s Equity Incentive Plan. He also received two stock option grants covering 16,000 shares each at an exercise price of $8.51 per share, expiring in 2036. Portions of the RSUs and options begin vesting on June 9, 2027, with remaining amounts vesting over time or in full by the earlier of that date or the next annual meeting of stockholders. Following these grants, one reported common stock position shows 16,000 shares held directly.
Vir Biotechnology director Janet Napolitano sold 3,200 shares of Common Stock in an open-market transaction at $9.45 per share. After the sale, she directly holds 21,216 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 27, 2025.
Vir Biotechnology, Inc. senior vice president and chief accounting officer Brent Sabatini reported an open-market sale of 379 shares of common stock at $9.45 per share. The trade was executed under a pre-arranged Rule 10b5-1 trading plan. After this small sale, he directly holds 61,902 shares.
The footnotes note that the 379 shares sold had been acquired on May 29, 2026 through an employee stock purchase program, indicating this filing reflects routine, pre-planned portfolio activity rather than a large discretionary transaction.
Vir Biotechnology director Charles Elliott Sigal reported equity awards and updated holdings. He received 8,000 restricted stock units under the company’s Equity Incentive Plan, which will vest in full on May 27, 2027. He also received stock options for 16,000 shares at an exercise price of $9.10 per share, vesting on the same date and expiring on May 26, 2036. After these grants, he holds 39,806 shares of common stock directly and 10,000 shares indirectly through Sigal Family Investments, LLC, for which he disclaims beneficial ownership beyond his economic interest.
Vir Biotechnology, Inc. director Janet Napolitano reported awards of company equity as part of compensation. She received 8,000 shares of Common Stock in the form of restricted stock units (RSUs) under the company’s Equity Incentive Plan. These RSUs will vest in full on May 27, 2027, meaning the shares become fully owned at that time.
She was also granted a stock option for 16,000 shares of Common Stock with an exercise price of $9.10 per share. The option will vest and become exercisable in full on May 27, 2027. Following the RSU grant, Napolitano directly holds 24,416 shares of Vir Biotechnology common stock, and holds the newly granted option covering 16,000 shares.
Vir Biotechnology, Inc. director Robert J. More reported equity awards and updated his holdings. He received 8,000 restricted stock units (RSUs) under the company’s Equity Incentive Plan, which will vest in full on May 27, 2027. He also received a stock option for 16,000 shares of common stock at an exercise price of $9.10 per share, vesting and becoming exercisable in full on May 27, 2027 and expiring on May 26, 2036. Following these awards, he directly holds 48,656 shares of common stock and 16,000 option shares. An additional 509,917 shares are held for the benefit of Alta Partners NextGen Fund I, L.P.; More may be deemed to beneficially own these through his role with its general partner but disclaims beneficial ownership except for his pecuniary interest.
Vir Biotechnology, Inc. director Jeffrey S. Hatfield reported receiving new equity compensation. He acquired 8,000 restricted stock units (RSUs) under the company’s Equity Incentive Plan, which will vest in full on May 27, 2027. He also received a stock option for 16,000 shares of common stock at an exercise price of $9.10 per share, vesting and becoming exercisable in full on May 27, 2027 and expiring on May 26, 2036. Following the RSU grant, he holds 39,806 shares of common stock directly. These awards are compensation-related grants rather than open-market purchases or sales.
Vir Biotechnology director Ramy Farid reported routine equity compensation awards. He received 8,000 shares of Common Stock as restricted stock units under the company’s equity incentive plan, bringing his direct holdings to 32,000 shares after the grant.
He was also granted a stock option for 16,000 shares of Common Stock at an exercise price of $9.10 per share. Both the RSUs and the option are scheduled to vest in full on May 27, 2027, and the option expires on May 26, 2036. These are compensation-related acquisitions, not open-market purchases.
Vir Biotechnology director Norbert W. Bischofberger reported equity awards rather than open-market trades. He received 8,000 shares in the form of restricted stock units granted under Vir Biotechnology’s Equity Incentive Plan, which will vest in full on May 27, 2027. He was also granted a stock option covering 16,000 shares of common stock at an exercise price of $9.10 per share, vesting on the same date and expiring on May 26, 2036. After these grants, he holds 21,333 shares of common stock directly and 10,667 shares indirectly through Nextquest, LLC, where he is a managing member.
Vir Biotechnology, Inc. director Vicki L. Sato reported an open-market sale of 22,000 shares of common stock on May 1, 2026 at a weighted average price of $10.0466 per share.
The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2025. After this transaction, she continues to hold 1,078,391 shares of Vir Biotechnology common stock directly.
Vir Biotechnology, Inc. director and President & CEO Marianne De Backer reported a restructuring of her common stock holdings. Two Form 4 transactions with code J reclassified a total of 467,064 shares at a stated price of $0.00 per share.
One entry moved 233,532 shares into indirect ownership held by the Ureel-De Backer Family Trust, where she and her spouse serve as trustees, following a transfer without consideration for tax and estate planning purposes. A parallel entry shows 233,532 shares under direct ownership, leaving her with 714,613 directly held shares and 286,650 indirectly held shares after these changes.
Vir Biotechnology, Inc. President and CEO Marianne De Backer had 72,559 shares of common stock automatically sold on 2026-04-06 at $9.156 per share. The footnotes state this sale occurred under a Rule 10b5-1 arrangement solely to satisfy the company’s tax withholding obligations related to vesting restricted stock units, and did not represent a discretionary trade by her.
After these transactions, she directly holds 948,145 shares of Vir Biotechnology common stock and indirectly holds 53,118 shares through the Ureel-De Backer Family Trust, where she and her spouse serve as trustees.
Vir Biotechnology director Vicki L. Sato sold shares under a pre-set trading plan. On April 1, 2026, she executed an open-market sale of 22,000 shares of Vir Biotechnology common stock at a weighted average price of $9.0735 per share pursuant to a Rule 10b5-1 trading plan adopted on March 27, 2025. After this transaction, she directly holds 1,100,391 shares of the company’s common stock.
Vir Biotechnology, Inc. senior vice president and chief accounting officer Brent Sabatini sold 7,711 shares of common stock in an open‑market transaction at a price of $9.12 per share on March 23, 2026. The filing shows he directly holds 61,902 shares after this sale. According to a footnote, the transaction was carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 19, 2025, indicating it was scheduled in advance as part of a trading program.
Vir Biotechnology EVP & CFO Jason O'Byrne reported an internal restructuring of 5,000 shares of Common Stock, described as a transfer without consideration for estate planning purposes. The filing shows 2,500 shares moved from his direct holdings and 2,500 shares recorded as indirectly held.
After these transactions, O'Byrne holds 160,115 shares directly and 2,500 shares indirectly through the O'Byrne Family Trust, where he and his spouse serve as trustees. The Form 4 does not reflect any open‑market buying or selling, but rather a non-cash reallocation of ownership.
Vir Biotechnology director Vicki L. Sato reported selling 22,000 shares of common stock in open-market transactions. The sales occurred on March 2, 2026 at weighted average prices of $9.5039 and $9.98 per share under a pre-arranged Rule 10b5-1 trading plan. After these sales, she directly owned 1,122,391 shares.
Vir Biotechnology director Vicki L. Sato reported option exercises and related share sales. She exercised a stock option for 42,377 shares of common stock at a price of $1.485 per share and received common shares upon exercise.
On the same date, she sold 42,377 common shares in open-market transactions, including 42,177 shares at a weighted average price of $9.7521 per share and 200 shares at $10.26 per share. The weighted-average sale involved multiple trades between $9.23 and $10.20 per share under a Rule 10b5-1 trading plan adopted on March 27, 2025. After these transactions, she directly owned 1,144,391 Vir Biotechnology common shares.
Vir Biotechnology, Inc. senior vice president and chief accounting officer Brent Sabatini reported an automatic sale of 1,430 shares of common stock. The shares were sold at an average price of $9.5326 per share under a Rule 10b5-1 plan to cover tax withholding on vested restricted stock units. After this non-discretionary transaction, he directly holds 69,613 shares.
Vir Biotechnology EVP & CFO Jason O'Byrne reported an automatic sale of 1,634 shares of common stock in an open-market transaction on February 24, 2026 at an average price of $9.5326 per share. According to the disclosure, this was a mandatory sale under a Rule 10b5-1 plan to cover the company’s tax withholding obligations tied to the vesting of restricted stock units, and not a discretionary trade by O'Byrne. After this tax-related sale, he beneficially owned 162,615 shares of Vir Biotechnology common stock.
Vir Biotechnology, Inc. executive vice president and chief medical officer Mark Eisner reported two open-market sales of common stock under a pre-set Rule 10b5-1 trading plan. On February 24, 2026, he sold 1,616 shares at an average price of $9.5326 per share. On February 25, 2026, he sold another 1,889 shares at an average price of $9.82 per share. A footnote states the February 25 sale was an automatic, mandatory sale to cover tax withholding from vested restricted stock units rather than a discretionary trade. After these transactions, Eisner directly owned 154,024 shares of Vir Biotechnology common stock.
Vir Biotechnology, Inc. executive Vanina de Verneuil, EVP, General Counsel and Corporate Secretary, reported two open-market sales of common stock. She sold 13,700 shares on February 25, 2026 at $9.82 per share and 3,117 shares on February 24, 2026 at $9.5326 per share.
The 13,700-share sale was an automatic, mandatory transaction under Rule 10b5-1 to cover tax withholding on vesting restricted stock units and was not a discretionary trade. The sales were executed pursuant to a Rule 10b5-1 trading plan adopted on June 2, 2025, and she held 112,982 shares directly after the last reported sale.
Vir Biotechnology, Inc. Chief Executive Officer Marianne De Backer reported an automatic sale of common stock tied to tax withholding. On this transaction date, 14,762 shares of common stock were sold in an open-market transaction at an average price of $9.5326 per share under a Rule 10b5-1 arrangement to satisfy the company’s tax withholding obligations related to vesting restricted stock units, and the filing states the sale was not a discretionary trade by her. After this sale, she held 1,020,704 shares of Vir Biotechnology common stock directly and 53,118 shares indirectly through the Ureel-De Backer Family Trust, where she and her spouse serve as trustees.
Vir Biotechnology SVP and Chief Accounting Officer Brent Sabatini reported both equity awards and an automatic tax-related sale of company stock. He received a grant of 25,000 shares of common stock as restricted stock units under Vir’s equity incentive plan and a stock option for 50,000 shares at an exercise price of $0.0000 per share. According to the vesting terms, 25% of the option will vest on February 22, 2027, with the remaining shares vesting in 36 equal monthly installments afterward. On February 23, 2026, 1,829 shares of common stock were sold at an average price of $7.4528 per share under a Rule 10b5-1 arrangement to satisfy tax withholding obligations tied to RSU vesting, and the filing states this sale was not a discretionary trade. After the tax-related sale, Sabatini directly owned 71,043 shares of Vir common stock, in addition to the newly granted 50,000 stock options.
Vir Biotechnology EVP & CFO Jason O'Byrne reported a mix of automatic tax-related sales and new equity awards. A total of 2,089 shares of common stock were sold on an open-market basis at $7.4528 per share under a Rule 10b5-1 arrangement solely to cover tax withholding on vesting restricted stock units, and the sale was not a discretionary trade.
On the prior day, O'Byrne received 55,000 shares of common stock as a restricted stock unit grant under the company’s equity incentive plan, bringing his common stock holdings to 166,338 shares at that time. He also received a stock option for 110,000 shares, with 25% vesting on February 22, 2027 and the remainder vesting in 36 equal monthly installments thereafter.
Vir Biotechnology EVP and Chief Medical Officer Mark Eisner reported a mix of stock grants and a small share sale. On February 22, 2026, he received 55,000 shares of common stock as a grant of restricted stock units and a stock option for 110,000 shares at an exercise price of $0.00. According to the terms, 25% of the option will vest on February 22, 2027, with the rest vesting in 36 equal monthly installments after that date. On February 23, 2026, 2,089 common shares were sold at an average price of $7.4528 per share under a Rule 10b5-1 arrangement to cover tax withholding on vesting RSUs, and this sale was described as automatic and mandatory rather than a discretionary trade. After these transactions, Eisner directly held 157,529 shares of common stock and the 110,000-share stock option.
Vir Biotechnology EVP and General Counsel Vanina de Verneuil reported a mix of stock sales and awards. On February 23, 2026, she completed an open-market sale of 4,445 shares of common stock at $7.4528 per share, described as an automatic, mandatory sale under a Rule 10b5-1 plan to cover tax withholding from vesting restricted stock units, rather than a discretionary trade. After this sale, she held 129,799 common shares directly.
On February 22, 2026, she acquired 55,000 shares of common stock through a grant of restricted stock units under the company’s equity incentive plan, and received a stock option for 110,000 shares. For the option, 25% of the shares will vest and become exercisable on February 22, 2027, with the remainder vesting in 36 equal monthly installments thereafter.
Vir Biotechnology, Inc. director and CEO Marianne De Backer reported both equity awards and a small share sale. On February 22, 2026, she received 570,000 stock options and 285,000 restricted stock units under the company’s equity plan, with options vesting 25% on February 22, 2027 and the rest in 36 monthly installments.
On February 23, 2026, 19,039 common shares were sold at $7.4528 per share in an automatic sale under a Rule 10b5-1 arrangement to cover tax withholding from RSU vesting, described as not a discretionary trade. After these transactions, she directly owned 1,035,466 common shares and indirectly held 53,118 shares via the Ureel-De Backer Family Trust.
Vir Biotechnology, Inc. executive Brent Sabatini, the SVP and Chief Accounting Officer, reported an automatic sale of 1,530 shares of common stock. The shares were sold in an open-market transaction at $7.79 per share to satisfy tax withholding obligations tied to vesting restricted stock units, under a Rule 10b5-1 arrangement.
The filing notes this was a mandatory, non-discretionary sale rather than a voluntary trade by Sabatini. After the transaction, he directly owned 47,872 shares of Vir Biotechnology common stock, reflecting his continuing equity stake in the company.
Vir Biotechnology director Vicki L. Sato reported a pre-planned stock sale. On 02/02/2026, she sold 22,000 shares of Vir Biotechnology common stock at a weighted average price of $7.7123 per share under a Rule 10b5-1 trading plan adopted on March 27, 2025.
After this transaction, she beneficially owns 1,144,391 shares directly. A Rule 10b5-1 plan allows insiders to schedule trades in advance, helping separate routine portfolio moves from trading based on nonpublic information.
Vir Biotechnology director Vicki L. Sato sold 22,000 shares of common stock on January 2, 2026 at a weighted average price of $5.9265 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2025.
Following this transaction, Sato beneficially owned 1,166,391 shares of Vir Biotechnology common stock, held in direct ownership.
Vir Biotechnology, Inc. (VIR) disclosed that major shareholder and director-affiliated entity SVF Endurance (Cayman) Limited reported two open-market sales of Vir common stock. On 11/24/2025, it sold 227,803 shares at a weighted average price of $6.1491, and on 11/25/2025 it sold 235,971 shares at a weighted average price of $6.38. The sales were made under a Rule 10b5-1 trading plan entered into on September 3, 2025. After these transactions, the reporting person indirectly beneficially owned 14,110,209 Vir common shares, held of record by SVF Endurance (Cayman) Limited.
Vir Biotechnology, Inc. reported an insider stock transaction by its EVP & Chief Financial Officer. On 11/17/2025, the officer sold 6,799 shares of Vir common stock at a price of $5.557 per share. The company states this was an automatic sale to cover tax withholding and remittance obligations tied to the vesting of restricted stock units, meaning it was done for tax purposes rather than discretionary selling. After this transaction, the officer beneficially owns 110,701 shares of Vir common stock, which includes 2,500 shares acquired on May 30, 2025 through an employee stock purchase program.
Vir Biotechnology (VIR) reported an insider transaction by its EVP, General Counsel and Corporate Secretary. On 11/05/2025, the officer sold 2,385 shares of common stock at $5.16 per share, as indicated by transaction code S. Following the sale, the officer beneficially owns 78,210 shares, held directly.
The filing notes the sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 5, 2024.
Vir Biotechnology (VIR) reported a Form 4 for insider activity. Vanina de Verneuil, EVP and General Counsel, executed an automatic sale of 1,365 shares of common stock at $5.863 on 11/03/2025 to satisfy tax withholding obligations upon RSU vesting.
After the transaction, she directly beneficially owns 80,595 shares. This total includes 2,500 shares acquired on May 30, 2025 through the employee stock purchase program.
Vir Biotechnology (VIR) director reported an open‑market sale of company stock. On 11/03/2025, the reporting person sold 22,000 shares of common stock at a weighted average price of $5.6385, coded “S”. The sale was made pursuant to a Rule 10b5‑1 trading plan adopted on 03/27/2025.
Following the transactions, the reporting person beneficially owned 1,210,391 shares, held directly. The shares were sold in multiple trades with prices ranging from $5.51 to $5.90.
Vir Biotechnology (VIR): Form 4 insider transactions disclosed. SVF Endurance (Cayman) Limited, affiliated with SoftBank Vision Fund (AIV M1) L.P. and managed by SB Investment Advisers (UK) Limited, reported open-market sales executed under a Rule 10b5-1 plan entered on September 3, 2025. On October 28, 2025, it sold 24,453 shares at a weighted average price of $6.5025, and on October 29, 2025, it sold 100 shares at $6.49. Following these trades, indirect beneficial ownership stood at 14,573,983 shares. The reporting relationship indicates Director status, and the filing is made by more than one reporting person.
Vir Biotechnology (VIR): insider share sales disclosed. SVF Endurance (Cayman) Limited, affiliated with SoftBank Vision Fund, reported open‑market sales of VIR common stock pursuant to a Rule 10b5‑1 plan entered on September 3, 2025.
On October 24, 2025, 46,696 shares were sold at a weighted average price of $5.9595, with trades ranging from $5.92 to $6.0212. On October 27, 2025, 66,403 shares were sold at a weighted average price of $6.0477, with trades ranging from $5.93 to $6.18. Following these transactions, 14,598,536 shares were beneficially owned on an indirect basis through SVF Endurance, as noted in the filing’s footnotes regarding SoftBank Vision Fund’s management structure.
Vir Biotechnology (VIR): insider transaction SVF Endurance (Cayman) Limited, affiliated with SoftBank Vision Fund, reported open‑market sales made pursuant to a Rule 10b5‑1 trading plan entered into on September 3, 2025.
It sold 144,266 shares on October 22, 2025 at a weighted average price of $6.1529, and 154,383 shares on October 23, 2025 at a weighted average price of $5.9898. After these transactions, the reporting person disclosed beneficial ownership of 14,711,635 shares, held indirectly.
Vir Biotechnology (VIR) insider filing shows affiliated entities of SoftBank reported open‑market sales of common stock. SVF Endurance (Cayman) Limited sold 220,535 shares on 10/20/2025 at a weighted average price of $6.1998 and sold 109,675 shares on 10/21/2025 at a weighted average price of $6.3002. The transactions were effected pursuant to a Rule 10b5‑1 trading plan entered on September 3, 2025.
Following these sales, the reporting persons showed indirect beneficial ownership of 15,119,959 shares after the 10/20/2025 trades and 15,010,284 shares after the 10/21/2025 trades, held through SVF Endurance (Cayman) Limited as described in the footnotes.
Vir Biotechnology (VIR): Form 4 insider transaction — SVF Endurance (Cayman) Limited, an affiliate of SoftBank Vision Fund, reported open‑market sales executed under a Rule 10b5-1 trading plan. On 10/15/2025, it sold 16,671 shares of common stock at a weighted average price of $6.0702. On 10/16/2025, it sold 12,844 shares at a weighted average price of $6.1014. Following these transactions, indirect beneficial ownership is reported as 15,340,494 shares. The filing notes the weighted‑average price ranges for each date and offers to provide full trade‑by‑trade detail upon request.
Vir Biotechnology (VIR): A reporting group affiliated with SoftBank—SVF Endurance (Cayman) Limited—reported open‑market sales of Vir common stock under a Rule 10b5‑1 trading plan entered into on September 3, 2025. On 10/09/2025, it sold 249,060 shares at a weighted average price of $6.1428. On 10/10/2025, it sold 2,300 shares at a weighted average price of $6.0752.
Following these transactions, the filing shows beneficial ownership of 15,372,309 shares after the first sale and 15,370,009 shares after the second, held indirectly, with SVF Endurance as record holder and SB Investment Advisers (UK) Limited managing SoftBank Vision Fund (AIV M1) L.P. The reporting person is listed as a Director and 10% Owner.
SVF Endurance (Cayman) Ltd and related SoftBank entities reported insider sales of Vir Biotechnology, Inc. (VIR) common stock under a Rule 10b5-1 plan. The filings show a sale of 72,133 shares on 10/07/2025 at a weighted average price of $5.6029 and a sale of 466,242 shares on 10/08/2025 at a weighted average price of $6.0479. After the reported transactions, the beneficial ownership attributable indirectly to the reporting group declined from 16,087,611 shares to 15,621,369 shares. The filings state the sales were effected pursuant to a 10b5-1 trading plan entered on September 3, 2025, and identify SVF Endurance as a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P., with SB Investment Advisers (UK) Limited acting as AIFM.
SVF Endurance (Cayman) Ltd and affiliated reporting persons disclosed insider sales of 524,297 shares of Vir Biotechnology, Inc. (VIR) across two dates in early October 2025. The sales occurred on 10/03/2025 and 10/06/2025 at weighted average prices of approximately $5.5553 and $5.6878, respectively, and were executed under a Rule 10b5-1 trading plan established on 09/03/2025. Following these disposals the reporting group beneficially owned 16,159,744 shares.
The filing clarifies that SVF Endurance (Cayman) Limited is the record holder and is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P., with SB Investment Advisers (UK) Limited appointed as the alternative investment fund manager responsible for investment decisions.
Vicki L. Sato, a director of Vir Biotechnology, Inc. (VIR), sold 22,000 shares of the company's common stock on 10/01/2025 under a Rule 10b5-1 trading plan adopted March 27, 2025. The reported weighted-average sale price was $5.8362 per share, with individual sale prices ranging from $5.68 to $5.99. After the reported disposition, the filing shows the reporting person beneficially owned 1,232,391 shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025 and includes an undertaking to provide detailed per-price sale breakdowns on request.